AIM
OREX

Acrospire Investment Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Acrospire Investment Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-700
Closed -$1K – 2746
2016
Q4 		$1K Buy
+700
New +$1.65K ﹤0.01% 2161

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Acrospire Investment Management's OREX Position: Q1 2017 in Review

Acrospire Investment Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2017, closing a stake of 700 shares — an estimated $1K sold.

Acrospire Investment Management first reported a position in OREX in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 52 funds tracked by Wall St. Rank hold OREX as of Q1 2017.

  • Acrospire Investment Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 700 Orexigen Therapeutics, Inc. shares in Q1 2017, an estimated $1K.
  • Acrospire Investment Management first reported a position in Orexigen Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Orexigen Therapeutics, Inc. position peaked at $1K in Q4 2016.
  • 52 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.